SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-36697

(Translation of registrant s name into English)

Green Square-B timent D

80/84 rue des Meuniers

92220 Bagneux France

(Address of principal executive office)

Indicate by check mark whether

the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as

permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is

submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,

thereunto duly authorized.

Bagneux, France, June 30, 2015

Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin Milk in Pediatric Cow s Milk Allergy

DSMB expressed no safety concerns and recommended that the study continue as planned

Initiation of Part B expected in the second half of 2015 pending consultation with regulatory agencies

DBV Technologies (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage, specialty biopharmaceutical company, today announced

the completion of Phase I or Part A, of the Viaskin Milk Efficacy and Safety Phase I/II study (MILES). The Data Safety Monitoring Board (DSMB) for the study recommended that the study continue and expressed no safety concerns after evaluating the

Part A safety data of subjects treated with a 150 g, 300 g and 500 g doses of Viaskin Milk.

The MILES study is a two part,

multi-center, double-blind, placebo-controlled, randomized clinical trial designed to evaluate the safety and efficacy of Viaskin Milk in IgE-mediated cow s milk protein allergic (CMPA)

patients ranging from two to 17 years of age. Part A evaluated the safety of three escalating doses of Viaskin Milk (150 g, 300 g and 500 g) versus placebo over three

weeks in 18 patients.

Pending review of the Part A data by the U.S. Food & Drug Administration (FDA) and U.S. and Canadian approvals of the

revised protocol described below, the Company intends to initiate Part B of the trial in the second half of 2015. Part B, or Phase II, of the MILES study is expected evaluate the efficacy and safety of all three doses of Viaskin Milk (150 g, 300 g, 500 g) versus placebo for 12 months. Approximately 176 patients between two and 17 years of age are expected to be randomized in a 1:1:1:1 ratio at

selected North American sites.

About the MILES Study

The MILES trial is a multi-center, double-blind, placebo-controlled, randomized Phase I/II trial to study the safety and efficacy of Viaskin Milk in pediatric

patient populations (age two to 17) suffering from IgE-mediated cow s milk protein allergy, or CMPA, with elevated IgE levels related to cow s milk protein. The trial is being conducted in select U.S. and Canadian clinical centers. Part A

of the MILES trial has been completed. Under the proposed amended MILES Part B protocol, up to 176 subjects are expected to be randomized for treatment at

approximately 18 sites. Eligible subjects with confirmed IgE-mediated CMPA will perform an initial food challenge at screening with escalating doses of cow s milk proteins. Subjects who

display objective signs or symptoms of allergic response to an eliciting dose of 300 mg cow s milk proteins (approximately 9.4 mL of cow s milk) or below will be randomized in the trial. The primary efficacy endpoint will be the percentage

of subjects who are treatment responders after 12 months, defined as subjects who meet at least one of the following criteria: (1) a 10-fold or greater increase in the cumulative reactive dose, or CRD, of cow s milk proteins at month 12 of

the food challenge as compared to baseline value in addition to reaching tolerance to at least 144 mg of cow s milk protein (approximately 4.5 mL of milk) or (2) a CRD of cow s milk protein greater than or equal to 1,444 mg

(approximately 45 mL of milk) at month 12 of the food challenge. Secondary efficacy endpoints include, among others, the percentage of subjects who are treatment responders at month 24, the mean and median CRD of cow s milk proteins at months

12 and 24 as well as the change in CRD from baseline, the change from baseline in the severity of symptoms elicited during the food challenge from baseline to months 12 and 24, and the change from baseline in quality of life assessments at months 12

About DBV Technologies

developing Viaskin , an innovative new approach to the treatment of allergies a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in

France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV

Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin

Peanut and Viaskin Milk. The clinical development program for Viaskin Peanut has received Fast Track designation and Breakthrough

Therapy designation from the U.S. Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN

code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:

Forward Looking Statements

This press release contains forward-looking statements, including statements about the potential safety and efficacy of Epicutenaous Immunotherapy (EPIT ) via Viaskin Milk and DBV s anticipated clinical development of Viaskin Milk and other product candidates. These forward-looking

statements are not promises or guarantees and involve substantial risks and uncertainties. The Company s product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ

materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be

predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the

Company s regulatory filings with the French Autorit des March s Financiers, the Company s Securities and Exchange Commission filings and reports, including in the Company s Annual Report on Form 20-F for the year ended

December 31, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies

undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.